Dauntless Investment Group LLC Makes New Investment in Tiziana Life Sciences Ltd (NASDAQ:TLSA)

Key Points

• Dauntless Investment Group LLC purchased 1,739,574 shares of Tiziana Life Sciences Ltd for approximately $1.88 million, making it 2.2% of their investment portfolio.
• Tiziana Life Sciences has shown significant price movement with a 12-month low of $0.63 and a high of $1.96.
• The company specializes in developing biotech solutions for human diseases, with its lead product candidate being Foralumab, aimed at treating various autoimmune conditions.

Dauntless Investment Group LLC acquired a new position in Tiziana Life Sciences Ltd (NASDAQ:TLSA - Free Report) in the first quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 1,739,574 shares of the company's stock, valued at approximately $1,879,000. Tiziana Life Sciences accounts for 2.2% of Dauntless Investment Group LLC's investment portfolio, making the stock its 4th largest position. Dauntless Investment Group LLC owned about 1.49% of Tiziana Life Sciences at the end of the most recent reporting period.

Separately, Bison Wealth LLC purchased a new stake in Tiziana Life Sciences in the 4th quarter worth approximately $30,000.

Tiziana Life Sciences Stock Down 4.4%

TLSA stock traded down $0.11 during midday trading on Friday, reaching $2.39. The company had a trading volume of 810,781 shares, compared to its average volume of 619,893. Tiziana Life Sciences Ltd has a 1 year low of $0.63 and a 1 year high of $2.60. The company has a 50 day moving average of $1.59 and a two-hundred day moving average of $1.26.

Tiziana Life Sciences Profile

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases.